AGM Statement

RNS Number : 6057U

Stem Cell Sciences plc

16 May 2008

 



Press Release

results of annual general meeting 15 may 2008 

("Stem Cell Sciences", "SCS")

16 May 2008

Stem Cell Sciences plc (AIM:STEM, ASX:STC) today announced that all the motions put to Members were approved at the AGM on a show of hands.

Set out below are the proxies received and results in respect of each motion as set out in the Company's Notice of Annual General Meeting put to the Members at the Annual General Meeting on 15 May 2008: 

1. Adoption of Annual Financial Report, including Directors' Report and Auditor's Report for the year   ended 31 December 2007.

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
13,002,181	0	0	49,729

The motion was carried on a show of hands as an ordinary resolution. 

2. To reappoint KPMG as auditors. 

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
12,998,172	2,000	2,009	49,729

The motion was carried on a show of hands as an ordinary resolution. 

3. Re-election of Dr Alastair Riddell as a Director

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
12,992,431	5,250	4,500	49,729

The motion was carried on a show of hands as an ordinary resolution. 

4. Re-election of Dr Peter Mountford, who under the Company's constitution which requires each director to be re-elected at least every three years, offered himself for re-election.

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
12,790,949	209,232	2,000	49,729

The motion was carried on a show of hands as an ordinary resolution. 

5. Re- election of Mr Leslie Webb, who under the Company's constitution which requires each director to be re-elected at least every three years, offered himself for re-election.

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
13,039,160	5,250	4,500	3,000

The motion was carried on a show of hands as an ordinary resolution. 

6. To allow the directors to issue of up to a third of the issued share capital via existing shareholders and allocate the residual shares in the share option pool.

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
12,750,735	131,250	4,009	165,916

The motion was carried on a show of hands as an ordinary resolution. 

7. To approve the issue of up to 15% of the issued share capital without reference to existing shareholders and allocate the residual shares in the share option pool.

The instructions given to validly appointed proxies in respect of the resolution were as follows:

Proxy Directed In Favour	Proxy Directed Against	Proxy Directed to Abstain	Proxy may Exercise Discretion
9,919,807	2,962,178	4,009	165,916

The motion was carried on a show of hands as an ordinary resolution. 

- Ends -

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)

Giorgio Reggiani, Finance Director & Company Secretary

[phone]

Halsin Partners (United Kingdom)

Michael Sinclair, Director

[phone]

Stem Cell Sciences Pty Ltd (Australia)

David Newton, Joint Company Secretary

[phone]

Talk Biotech (Australia)

Fay Weston, Director

[phone]

Notes to Editors

Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) in a leading provider of cells and cell culture media to the burgeoning stem cell research market. The successful application of stem cells in both research and clinical applications is the reproducible supply of pure, fully characterised stem cells and stem cell-derived specialised cells such as nerves and muscle. By providing these products, to the life sciences industry and academia for use in basic research and drug discovery, Stem Cell Sciences has multiple potential revenue streams.

Stem Cell Sciences has multiple industry collaborations, including Millipore Corporation for the marketing and distribution of HEScGRO™, its serum free media for the growth of human embryonic stem cells and Merck & Co for the use of mouse neural stem cell technology for research applications.

To access cutting edge technologies on a rapid and on-going basis, Stem Cell Sciences has built an exceptional network of highly interactive collaborations with academic centres of excellence in the stem cell field. These collaborations have been the source of our founding technologies and continue to provide an expanding pipeline of products and intellectual property that are central to the Company's strategy and success. 

For further information on the company please visit:  www.stemcellsciences.com. 

 

END

 

 

AGMUVVBRWKRVAAR